Patients undergoing chemotherapy with taxanes or anthracycline-containing regimens for breast, ovarian cancer, and Hodgkin’s disease had statistically significant increases in interferon (IFN)-α, IL-1β, IL-6, IL-8, IL-10, and monocyte chemoattractant protein 1 (MCP-1) (Wang et al., 2015). This evidence concerns the gene CCL2 and ovarian carcinoma.